A Retrospective Study of 657 Women With Vaginal Intraepithelial Neoplasia (VaIN)

Abstract Objective: The aim of this study was to explore the clinical characteristics of patients with VaIN and identify more sensitive diagnostic methods.Methods: This study retrospectively analyzed 657 patients with VaIN from the International Peace Maternal and Child Health Hospital in Shanghai during a ten-year period. Results: Among the 657 patients, 26.5% were diagnosed with VaIN 2/3. The proportions of patients with VaIN 2/3 among those who did and did not undergo hysterectomy were 39.5% and 24.7%, respectively. The sensitivity of cytology for VaIN in those with only VaIN, VaIN concomitant with cervical or vulvar lesions, and posthysterectomy VaIN was 56.7%, 66.5%, and 72.3%, respectively. The sensitivity of hrHPV for VaIN in the same categories was 87.7%, 86.5%, and 74.3%, respectively. The sensitivity of cytology and hrHPV cotesting for VaIN in the same categories was 95.2%, 95.6%, and 95.0%, respectively. In patients who did not undergo hysterectomy, HPV16 was detected in 9.5% of VaIN 1 lesions among the HPV DNA-positive patients, while the other 12 types of HPV were detected in 62.6% of VaIN 1 lesions. In patients who underwent hysterectomy, HPV16 was detected in 2.1% of VaIN 1 lesions, and the other 12 types of HPV were detected in 54.2% of VaIN 1 lesions.Conclusions: A combination of cytology and colposcopy could increase the sensitivity of the diagnosis of VaIN. The other 12 high-risk types of HPV positive may be more closely related to VAIN 1, more attention should be paid.

Download Full-text

Accuracy of colposcopic findings in detecting vaginal intraepithelial neoplasia: a retrospective study

10.1055/s-0040-1718187 ◽

2020 ◽

Author(s):

Stübs FA ◽

W Adler ◽

Beckmann MW ◽

P Gass ◽

A Hartmann ◽

...

Keyword(s):

Retrospective Study ◽

Intraepithelial Neoplasia ◽

Vaginal Intraepithelial Neoplasia

Download Full-text

Clinical presentation, treatment, and outcomes associated with vaginal intraepithelial neoplasia: A retrospective study of 118 patients

Journal of Obstetrics and Gynaecology Research ◽

10.1111/jog.14733 ◽

2021 ◽

Author(s):

Dake Yu ◽

Pengpeng Qu ◽

Meihua Liu

Keyword(s):

Retrospective Study ◽

Clinical Presentation ◽

Intraepithelial Neoplasia ◽

Vaginal Intraepithelial Neoplasia

Download Full-text

Erythroderma caused by vancomycin in children: concentration and speed of infusion

Mexican Journal of Medical Research ◽

10.29057/mjmr.v1i2.1787 ◽

2013 ◽

Vol 1 (2) ◽

Author(s):

José F. Luna Álvarez ◽

Mónica Gómez Vázquez ◽

Ana L. Moreno González ◽

Aldo Melchor Hernández ◽

Marco A. Escamilla-Acosta ◽

...

Keyword(s):

Adverse Reaction ◽

Clinical Practice ◽

Retrospective Study ◽

Clinical Characteristics ◽

Male Gender ◽

The Other ◽

Paediatric Hospital ◽

Other Hand ◽

Red Man Syndrome ◽

Main Factors

Vancomycin is an antibiotic glycopeptide that was isolated of the Streptomyces orientalis. It was introduced in the clinical practice for treatment of infections caused by staphylococcus in which other antibiotics were proving to be ineffective. In this retrospective study, we determine its prescription, clinical characteristics as well as the factors that favor the apparition of the erythroderma or red-man syndrome in a paediatric hospital. Forty patients to which physicians administer vancomycin and presented erythroderma were evaluated. Male gender was more predominated, with a total of 25 cases (62.5 %). The average age was of 12 ± 6 years. We identified two main factors that are directly related to the appearance of erythroderma. On one hand, the "concentration of the drug", which is related to the dilution that it is realized when a dose of vancomycin is going to be administered to the patient and on the other hand the “time or speed of infusion”. In the present study, it was found a low incident of this adverse reaction and few cases of complications.

Download Full-text

Current Perspectives in Human Papilloma Virus: Where We are and What We Need?

Biomedical & Pharmacology Journal ◽

10.13005/bpj/1798 ◽

2019 ◽

Vol 12 (04) ◽

pp. 1683-1700

Author(s):

B.S Anjali Devi ◽

Venugopal Reddy Bovilla ◽

SubbaRao V. Madhunapantula

Keyword(s):

Diagnostic Methods ◽

The Other ◽

Screening Methods ◽

Hpv 16 ◽

Hpv Dna ◽

Sequencing Technologies ◽

Public Health Screening ◽

Highly Sensitive ◽

Recent Developments ◽

Hpv 18

It is now well-established that Human Papilloma Viruses (HPV) are responsible for causing >90% of cervical cancers. Existing evidences have also demonstrated a key role for HPV in a portion of Head and Neck cancers as well as carcinomas of Vulva, Vagina, Penis and Anus. Therefore studies aiming at developing highly sensitive diagnostic methods have become high-priority in the recent years. To date, an estimated 202 types of HPV have been identified, of which only a small percentage viruses are involved in carcinogenesis. Among the carcinogenic HPV, the most predominant ones are HPV 16 and HPV 18. The other high risk types are 31, 33, 34, 35, 39, 45, 51, 52, 56, 58, 59, 66, 68, and 70. In general, HPV is detected by polymerase chain reaction (PCR) and hybrid capture (HC) methods. However, the existing PCR methods specifically identify only HPV 16 and HPV 18, but not the other types. More over, the PCR protocols are known for errors, and are not suitable for on-field screening procedures, hence, a suitable much quicker and sensitive method is required at the earliest. More over, the PCR and HC methods are expensive, hence, require more funds to conduct public health screening campaigns. Therefore, in this book chapter we have made an attempt to address the recent developments in HPV screening methods, and covered various advanced procedures available in the literature to identify HPV in patient specimens. For example, a section is dedicated to cover the “Biosensors”, which have been developed in detecting the HPV DNA in body fluids. These devices are much simpler compared to sequencing technologies and likely to be the next-generation detection devices for HPV

Download Full-text

Efficacy of adjunctive azithromycin versus single-dose cephalosporin prophylaxis for caesarean scar defect: study protocol for a randomised controlled trial

BMJ Open ◽

10.1136/bmjopen-2019-032379 ◽

2020 ◽

Vol 10 (1) ◽

pp. e032379

Author(s):

Yanqing Cai ◽

Hongjie Pan ◽

Jian Zhang ◽

Weiwei Cheng ◽

Yiru Shi ◽

...

Keyword(s):

Single Dose ◽

Child Health ◽

Protective Effect ◽

Controlled Trial ◽

Transvaginal Ultrasound ◽

International Peace ◽

Caesarean Scar ◽

Caesarean Scar Defect ◽

And Child Health ◽

Health Hospital

IntroductionPerioperative infections may be considered predictors of caesarean scar defect (CSD), and multidose antibiotics have a protective effect against CSD. However, the ability of adjunctive azithromycin combined with cephalosporin to reduce the prevalence of CSD remains unclear. The planned study aims to clarify the protective effect of antibiotics against CSD and to assess the effectiveness of adjunctive azithromycin prophylaxis for CSD.Methods and analysisThis study is a double-blind, parallel-control randomised clinical trial that will be carried out at the International Peace Maternity and Child Health Hospital. A total of 220 eligible patients will be randomised (1:1) to receive either adjunctive azithromycin or single-dose cephalosporin 30 min before the incision. The evaluation criteria are the prevalence and characteristics of CSD as assessed by transvaginal ultrasound (TVU) and saline infusion sonohysterography (SIS) at 42 days, 6 months and 12 months after delivery. The primary outcome will be the prevalence of CSD, and the characteristics of CSD will be assessed by TVU and SIS 42 days after delivery; all other outcomes are secondary.Ethics and disseminationThis protocol received authorisation from the Medical Research Ethics Committee of International Peace Maternity and Child Health Hospital on 25 April 2018 (approval no. GKLW2017-84). The findings will be reported in peer-reviewed publications and presentations at international scientific meetings.Trial registration numberChiCTR-INR-17013272.

Download Full-text